TAEK Proton Accelerator Facility Opened to Service

TAEK Proton Accelerator Facility inauguration event honored by the Prime Minister of Republic of Turkey, Mr. Recep Tayyip ERDOĞAN, was held on May 30th, 2012 in Sarayköy Nuclear Research and Training Center. Mr. Taner YILDIZ (Minister of Energy and Natural Resources), Mr. Binali YILDIRIM (Minister of Transport, Maritime Affairs and Communications), members of parliament, the Governor of Ankara, the Undersecretary of the Prime Ministry and representatives of  various institutions attended to this event.

 

 

The project scope included the construction of the building housing cyclotron type of accelerator and target systems, radiopharmaceutical production and quality control laboratories; construction of supporting buildings and infrastructure; supply, installation and tests of equipment and systems; personnel training.

First concrete was poured on February 24th, 2010 and the construction of the Facility was completed on December 10th, 2010. Installation and commissioning tests of cyclotron and target systems, equipment of radiopharmaceutical production and quality control laboratories were completed on March 7th, 2012. During commissioning tests; flourine-18, iodine-123, indium-111, gallium-67, thallium-201 and their radiopharmaceuticals were produced successfully.

The cyclotron system (Cyclone-30) designed by Ion Beam Application (IBA) has the state-of-art technological features of its kind. The proton beam energy is variable and the maximum energy is 30 MeV. The total beam current on target is also variable and the maximum current achievable is 1200 µA. The cyclotron designed by IBA is the first of a kind of its production line with respect to the ion source yielding the aforementioned maximum total proton current. The cyclotron system has four beam lines; three of them are used for radioisotope production and one for research and training.

TAEK-PAF is established to produce flourine-18, iodine-123, indium-111, gallium-67 and thallium-201 used for diagnosis of organs and several diseases such as cancer, neurological diseases, physiology of brain and its pathology, coronary diseases and heart imaging. The facility was designed to have enough flexibility to produce other radioisotopes upon demand. The production of radiopharmaceuticals, quality control and distribution of products as patient dose are conducted at the facility. Besides, research and training activities in nuclear field will be undertaken at the facility. The facility constitutes an important technological infrastructure for Turkey.